Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp*, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G.B. Langley, Chia Chi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, Christopher E.M. Griffiths

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

281 Scopus citations

Abstract

Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis. Methods: This phase III, multicenter, double-blind, placebo-controlled study randomized adults (2:1) to apremilast or placebo. At week 16, the placebo group switched to apremilast through week 32, followed by a randomized treatment withdrawal phase to week 52. Binary end points were analyzed using χ2 test; continuous end points used analysis of covariance. Results: In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast). At week 16, significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P < .0001; primary end point). Most (61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7% rerandomized to placebo. Of patients rerandomized to apremilast at week 32, mean percentage change from baseline PASI score was -88% to -81% (weeks 32-52). During the placebo-controlled period, 55.7% and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events. Most adverse events were mild/moderate in severity. No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period. Limitations: Data were limited to 52 weeks and may not generalize to nonplaque psoriasis. Conclusions: Apremilast was effective in moderate to severe plaque psoriasis.

Original languageEnglish (US)
Pages (from-to)37-49
Number of pages13
JournalJournal of the American Academy of Dermatology
Volume73
Issue number1
DOIs
StatePublished - Jul 1 2015

Keywords

  • ESTEEM
  • apremilast
  • clinical trial
  • phosphodiesterase 4 inhibitor
  • psoriasis
  • treatment

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)'. Together they form a unique fingerprint.

Cite this